The Far Out Initiative — Manifund Application

Project summary

The case for Valence Engineering rests on a single empirical fact, and the implications are larger than the fact suggests.

There exists a human being — Jo Cameron, identified by University College London in 2019 — who has lived her entire life without significant chronic physical pain, anxiety, depression, or grief, while retaining full agency, sociality, and emotional richness. Her case is not a thought experiment. It is the empirical refutation of the proposition that chronic suffering is the human condition. Not the price of consciousness. Not the cost of caring. Not the tax on ambition. Not psychological weather.

Cameron is the existence proof that the chronic affective load most human beings carry through their lives is not necessary — that it is output, the product of specific neural systems running in conditions they were not designed for. The architecture is real. It is biological. And it is, in principle, modifiable.

The Far Out Initiative is the public benefit company building the science to find out how, on terms governed by the Doorholder Covenant rather than commercial capture.

The scientific bet. Chronic suffering — chronic anxiety, chronic depression, chronic affective pain, the felt collapse of viable futures — is not a quantity of aversive sensation to be reduced by global pharmacological dampening. It is the output of a small number of identifiable neural circuits operating outside the conditions they evolved for: the lateral habenula's defeat-encoding system, the bed nucleus of the stria terminalis's chronic-vigilance system, the CGRP-expressing neurons of the parabrachial nucleus that stamp sensory input with felt emergency, and the dorsal anterior insula's interoceptive architecture that sets the ordinary ceiling on nondual and ecstatic states. These are control nodes. Address them precisely, and chronic suffering becomes addressable at a level no global pharmacological intervention can reach.

The political stakes. The chronic activation of these circuits is not, in significant part, an accident of modernity. The structures that won — the platforms, the markets, the management philosophies, the media architectures — won because they were better at capturing the outputs of a chronically stressed nervous system: attention, consumption, compliance, and the inability to organize an alternative. The suffering is not a side effect. It is the load-bearing wall on which those structures rest. This is not a conspiracy claim. It requires no conspirators, only selection. It is the political diagnosis the Manifesto develops in detail. Valence Engineering is the technical foundation for the alternative.

The intervention platform. Optical focused ultrasound paired with functional ultrasound imaging through sonolucent cranial windows, with focused-ultrasound-mediated blood-brain barrier opening as the eventual route to localized molecular and neurogenetic delivery. Reversible neuromodulation comes first, because reversibility is the precondition of error correction. Durable intervention comes only after the reversible mapping has earned it.

The shape of the contribution. The program now constitutes an integrated stack across five layers — conceptual, technical, measurement, payload, and governance — each load-bearing for the others. It is not a single device, a single target, or a single clinical indication. It is a staged intervention surface. The near-term ask is intentionally a proper subset of that surface, milestone-bounded and de-risked by reversible mapping. The full surface is visible only to qualified partners under NDA, and the discipline of the staging is the reason the full surface is worth taking seriously.

The integration is the contribution. What TFOI possesses is not any single insight that could be copied, but the working integration of conceptual, technical, measurement, payload, and governance work that no other program in the field is pursuing as an integrated whole. The reversible-mapping-then-localized-plasticity-reopening-then-state-induction protocol — the Correction's central technical pivot — is, as far as we know, not being pursued by any other group as an integrated protocol. A program containing any subset of these layers without the others would be a different and lesser program.

Four documents articulate the program. Three are public:

• The Paradise Engineering Manifesto — the founding statement of the work, the four-circuit thesis, the staged platform, and the Doorholder Covenant.

• The Correction — the technical autopsy of our earlier strategy and what we learned by killing it.

• The Gated Inheritance — the broader theory of inhibitory neural architecture inside which Valence Engineering is the first ethically urgent application.

The fourth — The Valence Engineering Research Prospectus — is the technical and strategic memo for collaborators and funders: original contributions, staged research roadmap, preclinical data plan, recruitment architecture, falsification criteria, dual-stream funding architecture, and full kill criteria. Available under NDA at founder@faroutinitiative.com.

A recent project update on this page — The Continuation — situates this application against the project's prior public history and the strategic pivot the corpus documents.

The full program is a multi-year, dual-funded (philanthropic + venture) research and development effort sized in the tens of millions over its first decade. This Manifund campaign raises $100,000 of bridge capital toward Stage 0, the foundation phase, during which the larger philanthropic and venture rounds are brought to closure with named partners now in conversation.

Project goals and how we will achieve them

The program's full goal is the development of a precision intervention science capable of addressing chronic suffering at the level of the circuits that produce and maintain it, governed by structural commitments to universal access and open architecture rather than commercial capture.

The program runs in two parallel research lanes, both governed by the Covenant. Lane A is clinical valence engineering — the translational path toward refractory suffering-related disorders, including treatment-resistant depression, severe chronic pain, and chronic anxiety, with surgical-candidate populations as the near-term clinical wedge. Lane B is gate and capacity mapping — the foundational research lane addressing the broader inhibitory architecture characterized in The Gated Inheritance. This includes self-boundary dissolution, nondual awareness, interoceptive quieting, agency restoration, perceptual disinhibition, autobiographical loosening, and the trait-level changes that contemplative traditions have always claimed are possible but science has never had the instruments to characterize. The lanes share the platform; they serve different evaluators; they reinforce each other scientifically and ethically.

The Stage 0 goals — what this campaign helps fund — are concrete and bounded. Over the next twelve months, founder-led work supported by this funding advances four parallel objectives:

1. Senior team conversion. Convert mapped target candidates across acoustics, optical focused ultrasound, functional ultrasound imaging, clinical neurosurgery, neurophenomenology, molecular delivery, and governance into formal advisor agreements, collaborator MOUs, or hires. Stage 0 funding is in significant part what makes this conversion credible to candidates evaluating the program.

2. Public scientific infrastructure. Continue producing the canonical documents the program operates under, plus the open field-level assets the program is designed to deliver: the construct dictionary that operationalizes awakening-relevant phenomenological constructs for rigorous measurement, the neurophenomenology protocol following the Petitmengin lineage, and the Proof / Promise / Unknown ledger that records the epistemic status of every major claim with an explicit next falsifying or validating step. These are reusable field assets, not TFOI-internal procedures. Adoption by other groups is the success metric.

3. Institutional and partnership groundwork. Legal, accounting, governance, and operational infrastructure required for a public benefit company to hold its commitments under scrutiny. Partnership development with the laboratories, clinical centers, and governance bodies whose participation Stage 0 ultimately delivers.

4. Closure of the larger Stage 0 rounds. A consciousness-science philanthropic round ($75K–$1M depending on partner) and a mission-aligned venture pre-seed ($3–5M) that funds the engineering, IP, and clinical-wedge work the dual-stream architecture requires. The Manifund tranche is what sustains the project through the closure window for both.

The strategic pivot the program rests on is the move from a chemistry-of-relief model to a control-architecture model of valence. That pivot was not free. It cost us a year of work, a partnership, and a team configuration. We made it because the old strategy could not pass the test the new one is shaped to: the intervention surface fits the grain of the problem.

How will this funding be used?

$100,000 over twelve months, allocated to founder-led continuity, public document production, legal and operational infrastructure, partnership development, and the conversion of mapped senior candidates into commitments. This is bridge capital — it sustains the work through the window in which the larger philanthropic and venture rounds (sized at $75K–$1M and $3–5M respectively) are brought to closure with partners now in active conversation.

The $100K figure corresponds to the Manifund-tier expression of the Stage 0 philanthropic floor described in The Valence Engineering Research Prospectus. It is the match, not the fire. The full Stage 0 program is sized at approximately $0.5M for senior team formation (months 0–9) and $3–5M for component prototypes (months 9–24). The Prospectus details the milestones, decision gates, and kill criteria that govern progression at every stage.

The minimum funding bar is set at $500. Anything raised above that figure extends the operational runway and the credibility signal to in-conversation partners proportionally.

Why a small, named bridge tranche matters strategically: the public record of regrantor support is the instrument that compounds. Partners in due diligence read it and decide accordingly. The $100K does not build the platform. It buys the runway and the institutional standing in which the platform is built.

The cost of underfunding this bridge is not symbolic. The four circuits this program targets are running, right now, in hundreds of millions of nervous systems — producing chronic depression, chronic anxiety, treatment-resistant pain, the felt collapse of viable futures — at a scale the existing psychiatric and pharmacological apparatus cannot reduce, because that apparatus is categorically mismatched to the architecture. SSRIs, talk therapies, and the rest of the standard of care were built on a model of suffering as something to be sedated or talked out of. They are not failing because they need refinement. They are failing because they are the wrong kind of intervention for the kind of problem chronic suffering is.

Every quarter of operational momentum lost is a quarter in which that load continues. The Manifund tranche is small. The work it bridges to is not.

Why the staging is the strength

Two architectural features of the program are worth surfacing explicitly, because together they distinguish Valence Engineering from speculative neurotechnology and give the Stage 0 ask its actual de-risking profile.

Reversible phenomenological mapping comes before any durable intervention. Focused ultrasound neuromodulation is reversible by construction — the effect on a circuit lasts as long as the protocol runs and decays after. The first phase of the program uses this reversibility as a research instrument: identify, in living human beings, which of the candidate circuits are not merely involved in chronic suffering but actionable in producing the changes the model predicts.

The reversible mapping is the program's primary de-risking mechanism. It pairs neural readouts with structured first-person reports, physiological measurement, behavioral data, and adverse-state monitoring. Every durable intervention proposed downstream rests on a circuit that has already shown itself, in reversible work, to do what the model predicts. A durable intervention on a circuit that fails reversible mapping is never proposed. This is the discipline the staging exists to enforce.

NHCMM is a bounded, asymmetric option, not a load-bearing assumption. The program does not depend on Non-Hermitian Complementary Acoustic Metamaterials maturing. The windowed Version 1 platform — focused ultrasound through sonolucent cranial windows, established and clinically tractable — produces the program's core scientific and clinical outputs regardless.

NHCMM is pursued in parallel as a high-variance research track with explicit kill criteria. If the benchtop work fails to demonstrate non-trivial active transmission improvement at 1–3 MHz through skull phantoms within the Stage 0/1 window, the moonshot is formally retired. The downside is bounded. The upside is asymmetric — if NHCMM matures, it becomes platform infrastructure for every transcranial ultrasound application in medicine, well beyond TFOI's scope. The program is structured so that funders are not betting on NHCMM. They are buying an option on it, paid for inside a research program whose value does not depend on the option being exercised.

Together these two features answer the question every donor at this stage should ask: what is the smallest commitment the program is asking me to make, and what is the program's discipline if it turns out to be partly wrong?

The answer: reversible mapping is the floor — even if the most ambitious downstream targets fail, the mapping itself produces standalone scientific value in neurophenomenology, consciousness science, and clinical-wedge interventions for refractory suffering-related conditions. The downstream durable intervention path is unlocked only by mapping that has earned it. The NHCMM moonshot is held to its own kill criteria. The program corrects publicly, in the manner The Correction has already demonstrated we can.

Why the Covenant matters

A research program that succeeds in addressing chronic suffering at the level of neural architecture creates a new class of power. The question of who that power belongs to, and on what terms is not separable from the science. It is part of the science.

TFOI is incorporated as a Public Benefit Corporation — a legal structure that binds the entity to its stated public mission as a matter of corporate law, not of founder character. The Doorholder Covenant operationalizes that binding. The Covenant requires universal access (not access for those who can pay), a suffering-weighted queue (not a market-cleared queue), open architecture (not proprietary lock-in), independent oversight (not founder discretion), and structural rather than aspirational implementation of all of the above.

These are not values statements. They are design constraints encoded into the institution such that the liberatory application is the path of least resistance and the coercive application is the path of maximum institutional friction, regardless of who is running the institution at any given time. The Covenant survives founder departure by design.

A second principle holds the Covenant in tension with proper epistemic humility. The ancestral inhibitory architecture was selected hard. Some of what it manages may be functions that have not yet been characterized. The research program is structured so that nothing irreversible occurs until the case for irreversibility has been built across years of stage-one and stage-two reversible work. This is the discipline that distinguishes serious neurotechnology from the failure modes of every previous attempt to engineer human affect at scale.

The Covenant is also what makes the work legitimately fundable at the philanthropic tier and the mission-aligned venture tier simultaneously. Philanthropic capital underwrites the field-level science and the open infrastructure. Venture capital underwrites the regulated clinical translation. The Covenant is the structural commitment that prevents either stream from capturing the work in ways that would betray the other.

Without the Covenant, the program is just another deep-tech bet whose outputs will reach the wealthy first and the suffering last. With it, the program is the foundation of a different kind of biotechnology: one whose design constraints were chosen before the science earned its leverage, by people who understood that the legitimacy of the science is inseparable from the legitimacy of its deployment.

This is the answer to the question every sophisticated donor will be asking at this point in the read: what prevents this from becoming another locked-up biotech that sells the therapy to the wealthy? The answer is a legal entity structure, a written covenant with specific structural commitments, and an institutional architecture being built to enforce both before the science arrives at the leverage point where capture would otherwise be inevitable.

Who is on the team? Track record on similar projects?

Joshua Michael Sparks, Founder and CEO. Founded TFOI in 2023. Author of The Paradise Engineering Manifesto, The Correction, The Valence Engineering Research Prospectus, and The Gated Inheritance — the broader theory of inhibitory neural architecture, of which Valence Engineering is the application whose moral case is so overdetermined that delay itself becomes the indictment. Carried the project through the strategic pivot from peripheral mimicry to circuit-level intervention. Further companion documents forthcoming.

Adam Summerfield, PhD, Chief Technology Officer. Doctorate in biogerontology with deep knowledge in biotechnology and genetic intervention techniques.

Manu Herrán, President. Long-tenured contributor to the foundations of suffering-focused ethics, predating the field's formal institutional recognition of itself.

Winslow Strong, Board Member. Pioneer in consciousness research, with foundational contributions to the field.

The senior scientific and engineering team that executes the full Stage 0 research program — across acoustics, OFUS source engineering, fUSI, clinical neurosurgery, neurophenomenology, molecular delivery, and governance — is mapped in The Valence Engineering Research Prospectus with target candidate pools identified for each role. Stage 0 is the conversion phase.

The candidates being converted are senior scientists and engineers whose existing work is in adjacent fields — focused-ultrasound neuromodulation, fUSI development, neurosurgical translation, contemplative neurophenomenology, acoustic metamaterials — and whose interest in TFOI is driven by the program's specific framing: a research question whose answer redefines what is possible for the human nervous system, governed by structural commitments that protect the science from capture, with kill criteria explicit enough to make the work legitimately risky rather than performatively so. Candidates of this caliber do not commit to projects that paper over their own failure modes. The corpus is, in part, the recruitment instrument.

Track record specifically relevant to this project:

In May 2024, Astral Codex Ten published a profile of the Far Out Initiative by Scott Alexander. That article generated the largest single body of public attention the project has received and brought it to the awareness of the rationalist, EA, and consciousness-research communities whose evaluation matters most to the work.

Two years later, we published The Correction — a public technical autopsy explaining why the program described in that ACX piece was wrong, why we killed it, and what replaced it. That document is, to our knowledge, an unusual artifact: a research organization publishing, in writing and with citations, an account of why its founding strategy was inadequate, before any external pressure forced the disclosure. We argue this is the most important track-record signal a research-stage organization can produce. The Correction is the public proof that the project meets the Dostoevsky standard the Doorholder Covenant requires: that the lie be exposed when the exposure costs more than the concealment.

The new program — circuit-level Valence Engineering on a focused-ultrasound platform, situated inside the broader theory of inhibitory architecture set out in The Gated Inheritance — was built from first principles, against the path of least resistance, in conditions in which continuing the old program would have been cheaper, easier, and more rewarded. That is the team's most directly relevant track record on a project of this kind: we have demonstrated, in public, the scientific honesty the work requires.

What are the most likely causes and outcomes if this project fails?

A note on this section: most fundraising documents minimize failure modes. We are listing them in detail because the discipline of doing so is the most important thing we can show a donor evaluating us. A research-stage organization that cannot articulate its own failure modes precisely cannot, by definition, be running the kind of program TFOI claims to run. What follows is the honest set.

The Valence Engineering Research Prospectus contains explicit kill criteria, decision gates, and Proof / Promise / Unknown disclosures for every major claim. We summarize the failure modes in their honest form here.

Failure mode 1: The four-circuit hypothesis is partly wrong. The current circuit map (lateral habenula, BNST, CGRP-parabrachial, dorsal anterior insula) is a candidate map. Each circuit has substantial published evidence behind it for its claimed function in chronic suffering, but the integrated four-circuit thesis is a synthesis. If reversible mapping reveals that one or more of the named circuits is not actionable in the way the model predicts — that intervention there does not produce the expected change in chronic affective load — the model updates. The phasic/chronic dissociation principle and the circuit-level intervention surface are robust to such updates; the specific target list is not. Outcome if this happens: the program publishes the null result, refines the target map, and proceeds with the surviving circuits.

Failure mode 2: The reversible mapping is feasible but the durable intervention path is not. Focused ultrasound neuromodulation is established and reversible. Focused-ultrasound-mediated blood-brain barrier opening for localized molecular delivery is in active clinical translation but is not yet a mature, proven durable intervention pathway. If the durable-intervention horizon proves longer or harder than the program currently estimates, the reversible-mapping work still produces standalone scientific value — neurophenomenological field-level assets, contributions to consciousness science, and clinical-wedge interventions in surgical-candidate populations. The program does not collapse if the long horizon recedes.

Failure mode 3: NHCMM does not mature. Non-Hermitian Complementary Acoustic Metamaterials are pursued as a parallel high-variance track that, if successful, would benefit every transcranial ultrasound application in medicine — not just TFOI's. The program does not depend on NHCMM. If the benchtop work fails to demonstrate non-trivial active transmission improvement at 1–3 MHz through skull phantoms within the Stage 0/1 window, the moonshot is formally retired and TFOI continues with the windowed Version 1 platform as the operating reality. The downside is bounded by explicit kill criteria.

Failure mode 4: Founder-led continuity fails before the larger rounds close. This is the failure mode the Manifund tranche directly addresses. If bridge capital is insufficient and the larger Stage 0 rounds do not close in time, the project loses operational momentum at the most expensive moment in its institutional development. The $100K ask is sized to make this failure mode unlikely, but not impossible. Donors should understand they are catalyzing a transition window, not underwriting a guaranteed outcome.

Failure mode 5: We are wrong in some way we have not yet recognized. This is the failure mode the Covenant is designed to surface. The Proof / Promise / Unknown ledger structure is intended to make every major claim's epistemic status visible, with an explicit next falsifying or validating step. If we are wrong, the structure of the program is designed to expose the wrongness publicly, in the manner The Correction already exposed our previous wrongness. The Correction is the public proof that this is not aspirational. We have done it once, in writing, when the disclosure was costly. We will do it again if the work requires it.

The honest summary: the most likely failure mode is not catastrophic. It is partial. We may be partly wrong about which circuits, may need longer than we currently estimate to mature the durable intervention path, may discover that one or more techniques requires more development than the current roadmap assumes. In each case the program updates, publishes the update, and continues on the corrected path. That is what the Doorholder Covenant requires and what The Correction has already demonstrated we can do.

The catastrophic failure mode — the one a donor should price in carefully — is that the institutional substrate fails before the science has time to mature. The $100K Manifund tranche is the smallest, most catalytic instrument we know of for reducing the probability of that specific failure.

How much money have you raised in the last 12 months, and from where?

Approximately $60,000 over the past twelve months, raised from a small group of early-stage individual backers — friends and proximate supporters of the work, several of whom hold investor backgrounds in adjacent areas. This funding has sustained founder-led continuity through the period of strategic pivot documented in The Correction and the production of the public corpus, including The Gated Inheritance and the forthcoming further companion documents.

This is, deliberately, a small base. The project has been operating in the foundational mode that Stage 0 requires: concentrated, document-producing, partnership-building, with deferred institutional fundraising until the corrected research program was articulated publicly and could be evaluated on its own terms. That articulation is now substantially complete. The Manifund campaign is the bridge between this preparatory phase and the larger Stage 0 philanthropic and venture rounds, sized at $75K–$1M and $3–5M respectively, that the corrected program is now ready to support.

One last frame, before the form fields.

The premise of this work — that chronic involuntary suffering is the output of a specific, identifiable, addressable neural architecture, and that addressing it carefully is owed to those who suffer — is either correct or it is not. We do not know yet. The corpus argues that the question is now answerable. The Stage 0 program is what answers it.

If we are wrong, you will know it, because we will publish it.

If we are right, you will have funded the infrastructure for the largest reduction in chronic human suffering that any single technological intervention has ever produced.

The Door is real, or it is not. We are building the instrument to find out. The $100,000 you are being asked to consider is what sustains the building of the instrument through the next twelve months.

Form fields

• Minimum funding (USD): $500

• Funding goal (USD): $100,000

• Decision deadline: 4 weeks from posting

• Cause areas: Biomedical (primary). Optionally also: Science & technology, Animal welfare. Avoid Global health & development.

• Country location: Brazil (and wherever other team members are operating from, if applicable)